ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and OrthoPediatrics (NASDAQ:KIDS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Earnings and Valuation
This table compares ClearPoint Neuro and OrthoPediatrics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ClearPoint Neuro||$20.55 million||6.21||-$16.43 million||($0.85)||-6.09|
|OrthoPediatrics||$122.29 million||4.47||$1.26 million||$0.09||260.00|
OrthoPediatrics has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
Risk & Volatility
ClearPoint Neuro has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for ClearPoint Neuro and OrthoPediatrics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ClearPoint Neuro presently has a consensus price target of $12.33, indicating a potential upside of 138.10%. OrthoPediatrics has a consensus price target of $53.33, indicating a potential upside of 127.92%. Given ClearPoint Neuro’s higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than OrthoPediatrics.
This table compares ClearPoint Neuro and OrthoPediatrics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
OrthoPediatrics beats ClearPoint Neuro on 10 of the 13 factors compared between the two stocks.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain. It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.